跳至主要内容
临床试验/ACTRN12608000174381
ACTRN12608000174381招募中不适用

A pilot study of dendritic cell (DC) vaccination using DCs pulsed with cell derived tumour antigen for stage IV melanoma following immune modulatory doses of chemotherapy to determine safety and tolerability.

niversity of Queensland0 个研究点目标入组 20 人开始时间: 2008年4月9日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
16 Years 至 ot stated(—)
性别
All

入选标准

  • All subjects
  • 1. Patients with metastatic stage IV metastatic melanoma not curable with standard therapy (radiotherapy or chemotherapy) and/or in whom standard therapy does not have proven survival benefits. This is relevant to the clinical state of the patient at the time of enrolment.
  • 2. Written informed consent
  • 3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (see Appendix 2)
  • 4. Subject judged to be able to safely undergo leukapheresis
  • 5. Age > 16.
  • 6. Life expectancy estimated to be greater than 4 months

排除标准

  • 1. Any concurrent therapy with possible activity against the patient’s malignancy with the exception of aminobisphosphonates
  • (local radiotherapy on lesions not essential for study evaluation is allowed)
  • 2. Concurrent therapy with any agent known to have immune modulating activity
  • 3. Any therapy with possible activity against the patient’s malignancy in the month preceding administration of first dose of study therapy
  • 4. Patient unable to undergo leukapheresis due to serious co-existing medical conditions
  • (particularly cardiac or cardiovascular) or for other reasons
  • 5. ECOG > 2
  • 6. Pregnant or breast feeding or at risk for becoming pregnant within 3 months of enrolment
  • 7. HIV, Hepatitis B or Hepatitis C positive
  • 8. Patients who need immediate therapy because of a disease related complication or in whom a complication is predicted on clinical suspicion, and for whom some standard therapy is available and appropriate in the clinical condition. This does not apply to disease symptoms for which non disease specific therapy (e.g. analgesia) would be routinely offered. Patients excluded because of these criteria can become eligible after the immediate medical need has been fully treated with standard therapy and one month has elapsed.

研究者

发起方
niversity of Queensland

相似试验